Literature DB >> 23913826

ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.

Longtao Wu1, Jonathan C Zhao, Jung Kim, Hong-Jian Jin, Cun-Yu Wang, Jindan Yu.   

Abstract

Chromosomal translocations juxtaposing the androgen-responsive TMPRSS2 promoter with the ETS-family transcription factor ERG result in aberrant ERG upregulation in approximately 50% of prostate cancers. Studies to date have shown important roles of ERG in inducing oncogenic properties of prostate cancer. Its molecular mechanisms of action, however, are yet to be fully understood. Here, we report that ERG activates Wnt/LEF1 signaling cascade through multiple mechanisms. ERG bound to the promoters of various Wnt genes to directly increase ligand expression. Consequently, ERG overexpression increased active β-catenin level in the cells and enhanced TCF/LEF1 luciferase reporter activity, which could be partially blocked by WNT-3A inhibitor IWP-2. Most importantly, our data defined LEF1 as a direct target of ERG and that LEF1 inhibition fully abolished ERG-induced Wnt signaling and target gene expression. Furthermore, functional assays showed that Wnt/LEF1 activation phenocopied that of ERG in inducing cell growth, epithelial-to-mesenchymal transition, and cell invasion, whereas blockade of Wnt signaling attenuated these effects. Concordantly, LEF1 expression is significantly upregulated in ERG-high human prostate cancers. Overall, this study provides an important mechanism of activation of Wnt signaling in prostate cancer and nominates LEF1 as a critical mediator of ERG-induced tumorigenesis. Wnt/LEF1 pathway might provide novel targets for therapeutic management of patients with fusion-positive prostate cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913826      PMCID: PMC3790861          DOI: 10.1158/0008-5472.CAN-13-0882

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

Review 1.  The many ways of Wnt in cancer.

Authors:  Paul Polakis
Journal:  Curr Opin Genet Dev       Date:  2007-02       Impact factor: 5.578

2.  Detection and analysis of beta-catenin mutations in prostate cancer.

Authors:  D R Chesire; C M Ewing; J Sauvageot; G S Bova; W B Isaacs
Journal:  Prostate       Date:  2000-12-01       Impact factor: 4.104

3.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.

Authors:  Jianghua Wang; Yi Cai; Chengxi Ren; Michael Ittmann
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

4.  APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers.

Authors:  Amy V Gerstein; Teresa Acosta Almeida; Guojing Zhao; Eric Chess; Ie-Ming Shih; Kent Buhler; Kenneth Pienta; Mark A Rubin; Robert Vessella; Nickolas Papadopoulos
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

5.  Wnt proteins are lipid-modified and can act as stem cell growth factors.

Authors:  Karl Willert; Jeffrey D Brown; Esther Danenberg; Andrew W Duncan; Irving L Weissman; Tannishtha Reya; John R Yates; Roel Nusse
Journal:  Nature       Date:  2003-04-27       Impact factor: 49.962

6.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.

Authors:  Kristiina Iljin; Maija Wolf; Henrik Edgren; Santosh Gupta; Sami Kilpinen; Rolf I Skotheim; Mari Peltola; Frank Smit; Gerald Verhaegh; Jack Schalken; Matthias Nees; Olli Kallioniemi
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

7.  Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.

Authors:  Alexandre de la Taille; Mark A Rubin; Min-Wei Chen; Francis Vacherot; Sixtina Gil-Diez de Medina; Martin Burchardt; Ralph Buttyan; Dominique Chopin
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

8.  Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.

Authors:  T Ohigashi; R Mizuno; J Nakashima; K Marumo; M Murai
Journal:  Prostate       Date:  2005-01-01       Impact factor: 4.104

9.  Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

Authors:  Gaoping Chen; Nicholas Shukeir; Anil Potti; Kanishka Sircar; Armen Aprikian; David Goltzman; Shafaat A Rabbani
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

10.  Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.

Authors:  Manju Sharma; William W Chuang; Zijie Sun
Journal:  J Biol Chem       Date:  2002-06-12       Impact factor: 5.157

View more
  45 in total

1.  Alcohol Consumption Modulates Host Defense in Rhesus Macaques by Altering Gene Expression in Circulating Leukocytes.

Authors:  Tasha Barr; Thomas Girke; Suhas Sureshchandra; Christina Nguyen; Kathleen Grant; Ilhem Messaoudi
Journal:  J Immunol       Date:  2015-11-30       Impact factor: 5.422

2.  Expression of ERG protein in prostate cancer: variability and biological correlates.

Authors:  Gustavo Ayala; Anna Frolov; Deyali Chatterjee; Dandan He; Susan Hilsenbeck; Michael Ittmann
Journal:  Endocr Relat Cancer       Date:  2015-06       Impact factor: 5.678

3.  Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway.

Authors:  Xiao-Fei Song; Qi-Hua Wang; Ran Huo
Journal:  Pathol Oncol Res       Date:  2017-11-14       Impact factor: 3.201

Review 4.  SOX4: The unappreciated oncogene.

Authors:  Carlos S Moreno
Journal:  Semin Cancer Biol       Date:  2019-08-21       Impact factor: 15.707

5.  LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a.

Authors:  Jiaqian Liang; Yirong Li; Garrett Daniels; Karen Sfanos; Angelo De Marzo; Jianjun Wei; Xin Li; Wenqiang Chen; Jinhua Wang; Xuelin Zhong; Jonathan Melamed; Jun Zhao; Peng Lee
Journal:  Mol Cancer Res       Date:  2015-01-13       Impact factor: 5.852

6.  Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Authors:  Noriko N Yokoyama; Shujuan Shao; Bang H Hoang; Dan Mercola; Xiaolin Zi
Journal:  Am J Clin Exp Urol       Date:  2014-04-15

Review 7.  Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue.

Authors:  Jian-Hua Luo; Silvia Liu; Ze-Hua Zuo; Rui Chen; George C Tseng; Yan P Yu
Journal:  Am J Pathol       Date:  2015-05-09       Impact factor: 4.307

Review 8.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

Review 9.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 10.  WNT signalling in prostate cancer.

Authors:  Virginia Murillo-Garzón; Robert Kypta
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.